Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update Read more about Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update Read more about Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors Read more about Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program Read more about Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program
Bellicum to Participate in Two Upcoming Virtual Investor Conferences Read more about Bellicum to Participate in Two Upcoming Virtual Investor Conferences
Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update Read more about Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)